Last updated on February 2017

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma


Brief description of study

This is a single arm open label, multicenter, non randomized, access study of trametinib for subjects with histologically confirmed cutaneous melanoma with a BRAF V600E/K positive mutation that is either advanced unresectable (stage IIIc) or distant metastatic (stage IV). Trametinib may be given as monotherapy or in combination since first line metastatic melanoma as per inclusion criteria. Subjects who received prior BRAF inhibitor may be included if they have not progressed under such treatment or if they have presented limited progression as per eligibility criteria. It is estimated that between 250 and 400 subjects with histologically confirmed cutaneous melanoma with a BRAF V600E/K positive mutation that is either advanced unresectable (stage IIIc) or distant metastatic (stage IV) will be enrolled.

Clinical Study Identifier: NCT02416232

Contact Investigators or Research Sites near you

Start Over

US GSK Clinical Trials Call ...

GSK Investigational Site
Amiens Cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Besancon cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Bordeaux, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Boulogne-Billancourt, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Caen Cedex 9, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Chambray-Les-Tours, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Clermont-Ferrand cedex 1, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Dijon Cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Grenoble cedex 9, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Le Mans, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Lille, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Limoges cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Lyon Cedex 08, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Marseille Cedex 5, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Montpellier cedex 5, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Nantes Cedex 1, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Nice, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Paris Cedex 10, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Paris, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Pau, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Poitiers, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Reims Cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Rennes Cedex, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Toulouse Cedex 9, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Vandoeuvre-Les-Nancy, France
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Villejuif cedex, France
  Connect »